Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease

被引：0
|
作者：
Schmidt, Andrew Lachlan
Anton, Angelyn
Wong, Shirley S.
Azad, Arun
Kwan, Edmond Michael
Spain, Lavinia Anne
Torres, Javier
Muthusamy, Arunbalaji
Parente, Phillip
Parnis, Francis
Goh, Jeffrey C.
Joshua, Anthony M.
Pook, David William
Gibbs, Peter
Tran, Ben
Weickhardt, Andrew James
机构：
[1] Dept Med Oncol, Brisbane, Qld, Australia
[2] Peter MacCallum Canc Ctr, Melbourne, Australia
[3] Western Hosp, Brunswick, ME, Australia
[4] Monash Hlth, Dept Med Oncol, Melbourne, Australia
[5] Monash Univ, Melbourne, Australia
[6] Goulburn Valley Hlth, Shepparton, Australia
[7] Austin Hlth, Melbourne, Vic, Australia
[8] Eastern Hlth, Melbourne, Vic, Australia
[9] Monash Univ, Eastern Hlth Clin Sch, Melbourne, Vic, Australia
[10] Adelaide Canc Ctr, Adelaide, SA, Australia
[11] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
[12] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[13] Monash Hlth, Dept Med Oncol, Melbourne, Vic, Australia
[14] Royal Melbourne Hosp, Melbourne, Vic, Australia
[15] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[16] Austin Hlth, Olivia Newton John Canc Wellness & Res Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
78
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease
    Schmidt, Andrew
    Anton, Angelyn
    Shapiro, Julia
    Wong, Shirley
    Azad, Arun
    Kwan, Edmond
    Spain, Lavinia
    Muthusamy, Arun
    Torres, Javier
    Parente, Phillip
    Parnis, Francis
    Goh, Jeffrey
    Joshua, Anthony M.
    Pook, David
    Gibbs, Peter
    Tran, Ben
    Weickhardt, Andrew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 (01) : 36 - 42
  • [2] Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
    Thomson, Alastair
    Pollard, Adam
    Mark, Frances May
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [3] Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Karnes, R. Jeffrey
    Ahmed, Mohamed E.
    APPLIED RADIOLOGY, 2021, 50 (01) : 42 - 43
  • [4] Elderly patients with metastatic castrate-resistant prostate cancer (mCRPC): Safety and efficacy of docetaxel retreatment
    Gernone, A.
    Pagliarulo, A.
    Calderoni, G.
    Pagliarulo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [5] Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Theoret, Marc Robert
    Arlen, Philip M.
    Dawson, Nancy Ann
    Rosner, Inger L.
    McLeod, David G.
    Wright, John Joseph
    Cordes, Lisa M.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Trepel, Jane B.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [6] Trends in prescribing preferences (PPrefs) of US-based oncologists for patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC) following docetaxel (DO).
    Ryan, Charles J.
    Kim, Won
    Buettner, Arden
    Britton, Susan Lynne
    Lankford, Maria L.
    Neely, Doug B.
    Green, Mark R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [7] Overall survival (OS) prognostic factors in metastatic castrate-resistant prostate cancer (mCRPC) patients retreated with docetaxel (D)
    Shah, Shilpa Rashmikant
    Albany, Costantine
    Hahn, Noah M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Phase I study of apalutamide (ARN) plus abiraterone acetate (AA), docetaxel (D) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Molina, A. M.
    Christos, P. J.
    Whang, Y.
    Nordquist, L.
    Hackett, A. L.
    Beltran, H.
    Faltas, B.
    Nanus, D.
    Giannakakou, P.
    Tagawa, S. T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Comparison of survival of African-American (AA) patients (pts) in docetaxel (D)-based combination therapies in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Ning, Yang-Min
    Theoret, Marc Robert
    Arlen, Philip M.
    Parnes, Howard L.
    Ojemuyiwa, Michelle A.
    Strauss, Julius
    Dawson, Nancy Ann
    McLeod, David G.
    Harold, Nancy
    Couvillon, Anna
    Cordes, Lisa M.
    Chen, Clara
    Steinberg, Seth M.
    Sissung, Tristan M.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [10] Correlation of increased eosinophil count following sipuleucel-T treatment with outcome in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
    McNeel, Douglas G.
    Lin, Daniel W.
    Gardner, Thomas
    Sheikh, Nadeem A.
    Whitmore, James Boyd
    Sims, Robert Brownell
    Dreicer, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345